Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.47 |
| ▸ | ATR | Q13535 | 5/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.40 |
| ▸ | NEK2 | P51955 | 5/20 | 0.40 |
| ▸ | PRKDC | P78527 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | NNMT | P40261 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | PLAU | P00749 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL360918 | 0.86 | SIRT6 (0.47) | SIRT6ATRMAP4K4NEK2TDP1 | |
| SCHEMBL4253359 | 0.86 | NPSR1 (0.47) | SIRT6ATRPRKDCNNMTKDM4E | |
| SCHEMBL11907385 | 0.83 | ATR (0.44) | SIRT6ATRNEK2PRKDC | |
| SCHEMBL410727 | 0.77 | ATR (0.58) | ATRPRKDCTDP1KDM4EALDH1A1 | |
| SCHEMBL10328705 | 0.76 | POLB (0.51) | SIRT6TDP1NNMTPOLBLMNA | |
| SCHEMBL361688 | 0.76 | SIRT6 (0.44) | SIRT6TDP1NNMTPOLBLMNA | |
| SCHEMBL3575758 | 0.76 | GRM5 (0.53) | ATRMAP4K4PRKDCPOLBKDM4E | |
| SCHEMBL30206007 | 0.75 | SIRT6 (0.43) | SIRT6TDP1NNMTPOLBLMNA | |
| SCHEMBL17325906 | 0.75 | SIRT6 (0.51) | SIRT6NNMTPOLBKDM4EALDH1A1 | |
| SCHEMBL30296534 | 0.75 | SIRT6 (0.43) | SIRT6TDP1NNMTPOLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181968-A1 | Novel 3-Bicyclocarbonylaminopyridine-2-Carboxamides or 3-Bicyclocarbonylaminopyrazine-2-Carboxamides | ASTRAZENECA AB (SE) | 2009-07-16 | — | — | US | claimed |
| CN-101336238-A | Novel bicyclic carbonylaminopyridine-2-carboxamides or 3-bicyclic carbonylaminopyrazine-2-carboxamides | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | CN | claimed |
| US-8846658-B2 | Oxazine derivatives and their use in the treatment of neurological disorders | NOVARTIS AG (CH) | 2014-09-30 | — | — | US | disclosed |
| US-20140113894-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CN) | 2014-04-24 | — | — | US | disclosed |
| US-20090181968-A1 | Novel 3-Bicyclocarbonylaminopyridine-2-Carboxamides or 3-Bicyclocarbonylaminopyrazine-2-Carboxamides | ASTRAZENECA AB (SE) | 2009-07-16 | — | — | US | disclosed |
| US-20090181968-A1 | Novel 3-Bicyclocarbonylaminopyridine-2-Carboxamides or 3-Bicyclocarbonylaminopyrazine-2-Carboxamides | ASTRAZENECA AB (SE) | 2009-07-16 | — | — | US | disclosed |
| US-20090181968-A1 | Novel 3-Bicyclocarbonylaminopyridine-2-Carboxamides or 3-Bicyclocarbonylaminopyrazine-2-Carboxamides | ASTRAZENECA AB (SE) | 2009-07-16 | — | — | US | disclosed |
| CN-101336238-A | Novel bicyclic carbonylaminopyridine-2-carboxamides or 3-bicyclic carbonylaminopyrazine-2-carboxamides | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | CN | disclosed |
| EP-1957478-A2 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007061360-A2 | NOVEL 3-BICYCLOCARBONYLAMINOPYRIDINE-2-CARBOXAMIDES OR 3-BICYCLOCARBONYLAMINOPYRAZINE-2-CARBOXAMIDES | ASTRAZENECA AB (SE) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007061360-A2 | NOVEL 3-BICYCLOCARBONYLAMINOPYRIDINE-2-CARBOXAMIDES OR 3-BICYCLOCARBONYLAMINOPYRAZINE-2-CARBOXAMIDES | ASTRAZENECA AB (SE) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181968-A1 | Novel 3-Bicyclocarbonylaminopyridine-2-Carboxamides or 3-Bicyclocarbonylaminopyrazine-2-Carboxamides | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNA2, CNR2 | SIRT6 418/4885ATR 3434/4885MAP4K4 3285/4885 |
| US-20140113894-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | OTC, GRIK5, GRIN2C | SIRT6 1402/4885ATR 3118/4885MAP4K4 2727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.